Communiqués MacroGenics, Inc.

Actions

MGNX

US5560991094

Recherche biotechnologique et médicale

Temps réel estimé Cboe BZX 21:08:02 02/09/2026			Varia. 5j.	Varia. 1 janv.
4,255 ^USD	+5,32 %		+4,83 %	+163,04 %

17/08	MacroGenics, Inc. : B. Riley favorable sur le dossier	ZM
13/08	MacroGenics, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI

Communiqués

13/08	MacroGenics: Q2 Earnings Snapshot	AQ
13/08	MacroGenics : Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position Announced sale of manufacturing operations ( July 2026) for $122.5 million and transition to fully outsourced model with leaner, approximately 140-person workforce focused on novel therapeutics pipeline Data presentations at ESMO planned for MGC026 (B7-H3 ADC) and lorigerlimab (PD-1 × CTLA-4)	PU
13/08	MacroGenics Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position	AQ
11/08	MacroGenics Announces Achievement of $10 Million Milestone Following Gilead’s Exercise of Option to License Preclinical Bispecific Program	GL
23/07	MacroGenics Provides Clinical Update on Ongoing Phase 1 Study for MGC026	GL
02/07	MacroGenics Completes Sale of GMP Manufacturing Operations to Bora Pharmaceuticals ROCKVILLE, MD, July 02, 2026 (GLOBE NEWSWIRE) MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, and Bora Pharmaceuticals Co., Ltd. (TWSE: 6472; OTCQX: BORAY), a global leader in	PU
02/07	MacroGenics Completes Sale of GMP Manufacturing Operations to Bora Pharmaceuticals	GL
22/06	MacroGenics to Receive Milestone Payment from Sanofi for Recent TZIELD® Approval	GL
14/05	MacroGenics to Participate in the Stifel 2026 Virtual Targeted Oncology Forum	GL
13/05	MacroGenics : Reports First Quarter 2026 Financial Results and Highlights Business Transformation Manufacturing operations divestiture sharpens focus on core capabilities in novel drug discovery and development Manufacturing divestiture and expanded monetization of ZYNYZ royalty anticipated to provide up to $202.5 million in combined proceeds ADC pipeline remains on track for multiple data	PU
13/05	MacroGenics: Q1 Earnings Snapshot	AQ
13/05	MacroGenics Reports First Quarter 2026 Financial Results and Highlights Business Transformation	AQ
11/05	MacroGenics to Sell GMP Manufacturing Operations to Bora Pharmaceuticals •MacroGenics to receive $122.5 million upfront payment from Bora upon closing •Transaction includes transfer of manufacturing site, CDMO operations and associated personnel to Bora ROCKVILLE, MD, May 11, 2026 (GLOBE NEWSWIRE) MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical	PU
11/05	MacroGenics to Sell GMP Manufacturing Operations to Bora Pharmaceuticals	GL
04/05	MacroGenics and Sagard Healthcare Partners Enter into Expanded ZYNYZ® Royalty Purchase Agreement	GL
08/04	FDA Removes Partial Clinical Hold on MacroGenics’ LINNET Study	GL
09/03	MacroGenics: Q4 Earnings Snapshot	AQ
09/03	MacroGenics : Corporate Overview March 2026	PU
09/03	MacroGenics Reports 2025 Financial Results and Highlights Upcoming Planned Data Disclosures	AQ
26/02	MacroGenics to Participate in Upcoming Investor Conferences	GL
24/02	MacroGenics Announces Pausing of Enrollment of New Study Participants in LINNET Trial FDA has placed partial clinical hold on LINNET study of lorigerlimab in gynecologic cancer ROCKVILLE, MD, Feb. 23, 2026 (GLOBE NEWSWIRE) MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of	PU
24/02	MacroGenics Announces Pausing of Enrollment of New Study Participants in LINNET Trial	GL
12/01	MacroGenics : Corporate Overview 2026 01 11 (JPM) vF	PU
25/11	MacroGenics to Participate in the 8th Annual Evercore Healthcare Conference	GL
13/11	MacroGenics : Corporate Overview 2025 11 13 vF	PU